{"entity":{"id":"chd2","kind":"target","name":"CHD2","aka":["chromodomain helicase DNA binding protein 2","ATP-dependent chromatin remodeler CHD2","FLJ38614","DKFZp547I1315","DKFZp781D1727","DKFZp686E01200"],"tldr":"CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.","summary":"ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3. Involved in myogenesis via interaction with MYOD1: binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression.\n\nIntOGen calls it a driver in 7 cohorts (3 activating, 4 loss-of-function), covering Bladder Urothelial Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Gastrointestinal Stromal Tumour, Papillary Renal Cell Carcinoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:1917","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1917"},{"label":"UniProt O14647","url":"https://www.uniprot.org/uniprotkb/O14647/entry"},{"label":"NCBI Gene 1106","url":"https://www.ncbi.nlm.nih.gov/gene/1106"},{"label":"Ensembl ENSG00000173575","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173575"}],"tags":["cancer-genes-wave"],"related":["open-targets","intogen"],"cancers":["leukaemia","non-hodgkin-lymphoma","urothelial","rcc","all-leukemia","cll","gist","papillary-rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts. Evidence tier \"cohort-driver\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CHD2","role":["oncogene-driver","tumour-suppressor"],"evidenceTier":"cohort-driver","sources":[{"label":"HGNC HGNC:1917","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1917","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O14647","url":"https://www.uniprot.org/uniprotkb/O14647/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000173575","url":"https://platform.opentargets.org/target/ENSG00000173575/associations","note":"per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.72, B-cell chronic lymphocytic leukaemia 0.71, non-Hodgkin lymphoma 0.72, leukaemia 0.74 (GraphQL API, CC0)"},{"label":"IntOGen CHD2","url":"https://www.intogen.org/search?gene=CHD2","note":"driver in 7 cohorts (Act 3, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:1917","ensembl":"ENSG00000173575","uniprot":"O14647","entrez":"1106","biology":"ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3. Involved in myogenesis via interaction with MYOD1: binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression. Location: Nucleus (UniProt). Locus 15q26.1 (HGNC).","whereFound":["Leukaemia: Open Targets association 0.74 with leukaemia (MONDO_0005059)","Non-Hodgkin lymphoma: Open Targets association 0.72 with non-Hodgkin lymphoma (MONDO_0018908)","Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)","Renal cell carcinoma: IntOGen driver in 1 cohort (PRCC)","Acute lymphoblastic leukaemia: Open Targets association 0.72 with acute lymphoblastic leukaemia (MONDO_0004967)","Chronic lymphocytic leukaemia: Open Targets association 0.71 with B-cell chronic lymphocytic leukaemia (MONDO_0004948); IntOGen driver in 4 cohorts (CLLSLL)"],"targetClass":"transcription","prevalence":[]},"route":"/targets/chd2/","neighbours":{"collection":[{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}]}}